Haemonetics Stock Net Income
| HAE Stock | USD 94.40 1.07 1.15% |
Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 132.7 M | 139.3 M | |
| Net Income Applicable To Common Shares | 132.7 M | 139.3 M | |
| Net Income From Continuing Ops | 132.7 M | 139.3 M | |
| Net Income Per Share | 0.86 | 0.58 | |
| Net Income Per E B T | 0.76 | 0.42 |
Haemonetics | Net Income |
Haemonetics Company Net Income Analysis
Haemonetics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Haemonetics Net Income | 115.4 M |
Most of Haemonetics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Haemonetics Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Net Income. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Haemonetics Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Haemonetics reported net income of 115.4 M. This is 66.19% lower than that of the Health Care Equipment & Supplies sector and 15.82% higher than that of the Health Care industry. The net income for all United States stocks is 79.79% higher than that of the company.
Haemonetics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.Haemonetics is currently under evaluation in net income category among related companies.
Haemonetics Institutional Holders
Institutional Holdings refers to the ownership stake in Haemonetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Haemonetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Haemonetics' value.| Shares | Dimensional Fund Advisors, Inc. | 2023-12-31 | 826.7 K | Amvescap Plc. | 2023-12-31 | 715.9 K | Westfield Capital Management Company, Lp | 2023-12-31 | 712.1 K | Btim Corp | 2024-03-31 | 711.9 K | Fisher Asset Management, Llc | 2023-12-31 | 711.7 K | Boston Partners Global Investors, Inc | 2023-12-31 | 707.4 K | Schroder Investment Management Group | 2023-12-31 | 656.8 K | Northern Trust Corp | 2023-12-31 | 628.5 K | Charles Schwab Investment Management Inc | 2023-12-31 | 534.7 K | Capital Research Global Investors | 2023-12-31 | 6.5 M | Blackrock Inc | 2023-12-31 | 6 M |
Haemonetics Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0612 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 5.47 B | ||||
| Shares Outstanding | 50.79 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 2.24 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.59 X | ||||
| Price To Sales | 3.41 X | ||||
| Revenue | 1.17 B | ||||
| Gross Profit | 530.77 M | ||||
| EBITDA | 249.34 M | ||||
| Net Income | 115.4 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 765.89 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 18.57 X | ||||
| Cash Flow From Operations | 273.06 M | ||||
| Short Ratio | 5.08 X | ||||
| Earnings Per Share | 2.46 X | ||||
| Price To Earnings To Growth | 1.63 X | ||||
| Target Price | 105.57 | ||||
| Number Of Employees | 3.03 K | ||||
| Beta | 0.36 | ||||
| Market Capitalization | 4.79 B | ||||
| Total Asset | 1.93 B | ||||
| Retained Earnings | 253.17 M | ||||
| Working Capital | 517.91 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
| Net Asset | 1.93 B |
About Haemonetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Haemonetics Investors Sentiment
The influence of Haemonetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Haemonetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Haemonetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Haemonetics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Haemonetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Haemonetics' short interest history, or implied volatility extrapolated from Haemonetics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 2.46 | Revenue Per Share 25.092 | Quarterly Revenue Growth 0.101 | Return On Assets 0.0612 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.